Under the Medicare Modernization Act, the United States Pharmacopeia (USP) is required to develop and update a formulary template, the USP Model Guidelines Version 3.0, for use by Medicare Part D Plans in developing their formularies. These guidelines are voluntary. The USP Model Guidelines includes a Formulary Key Drug Type (FKDT) for NK1 Receptor Antagonists for benefit year 2008.
Selected Important Risk Information
EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
[PDF: 495 KB]
